Research
Hormonal
Retatrutide (LY3437943) is relatively safe and supports once-weekly dosing.
Practitioners can consider retatrutide as a potentially safe option for treatment with a convenient dosing schedule.
StrongSupportsmedium confidence
Retatrutide was relatively safe and pharmacokinetics support once-weekly dosing.
Why this rating
Based on the phase 1b clinical trial design mentioned in the abstract.
Source
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
Sheila A Doggrell · Expert Opinion on Investigational Drugs · 2023
DOI 10.1080/13543784.2023.2206560
otherCited 30×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →